What he means is that when you write: "whilst many critics may see Her Vaxx as a fail, it definitely is not"
But then write: "The difficulty is in marrying it with a Big Pharma pipeline in combination with their existing suite of products .... Therefore reaching a sound commercial outcome has proven difficult for Imugene"
You're missing the elephant in the room. Which is after 10 years and tens of millions spent, failing to achieve a commercial outcome for HER-Vaxx is "definitely a fail".
I'd add that failing to admit it and failing to keep shareholders informed compounds the scientific fail with a bit of management-can't-be-trusted fail.
What he means is that when you write: "whilst many critics may...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
-0.001(1.41%) |
Mkt cap ! $512.3M | |||
| Open | High | Low | Value | Volume |
| 7.2¢ | 7.4¢ | 7.0¢ | $1.229M | 17.36M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 707803 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.1¢ | 172396 | 5 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.1¢ |
Change
-0.001 ( 1.25 %) |
||||
| Open | High | Low | Volume | ||
| 7.2¢ | 7.3¢ | 7.0¢ | 6411396 | ||
| Last updated 15.59pm 15/05/2024 ? | |||||
| IMU (ASX) Chart |